| Systematic (IUPAC) name | |
|---|---|
| (2R,3S,4S)-2-butyl-3-p-tolylquinuclidine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Legal |
| Identifiers | |
| ATC code | ? |
| PubChem | CID 9903250 |
| Chemical data | |
| Formula | C18H27N |
| Mol. mass | 257.414 g/mol |
| SMILES | eMolecules & PubChem |
| |
|
2-Butyl-3-(p-tolyl)quinuclidine (BTQ) is a stimulant DRI.[1] It is one of a number of substituted quinuclidine derivatives developed as potential medications for the treatment of cocaine abuse,[2] and produces similar effects to cocaine in animal studies, although milder and longer lasting.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)